MEDICAL
MindMed | January 21, 2021
MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland.
If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and nervousness that are sometimes associated with LSD - creating a general more good experience.
MindMed is undertaking a Phase 1 clinical preliminary to assess if MDMA, when adjusted and utilized in combination with LSD, can help offset a portion of the known expected horrendous impacts of LSD that happen in treatment or clinical settings. MindMed is keen on arrangement how to adjust both MDMA and LSD in a strong manner to make better patient results, and grow further developed hallucinogenic helped treatments, as MindMed extends the two its R&D and commercial drug improvement pipeline. The examination is foreseen to take around one year to finish.
Read More
MEDICAL
Novalis Biotech | July 01, 2021
Novalis Biotech, an early-stage venture capital investor in healthcare-related technology, announced today the completion of its €25 million second fund, the Novalis Biotech Acceleration Fund. The fundraising has included both new and returning investors. The second fund's investor base comprises institutional investors, including Participate Maatschappij Vlaanderen (PMV), family offices, and high-net-worth individuals (HNWIs).
The Biotech Acceleration Fund will continue to invest in start-up and scale-up companies that use "enabling technologies" to improve healthcare. Genomic and bioinformatics technologies, drug research and manufacturing tools, diagnostics, and personalized medicine are examples. The funds will be divided between early-stage incubation initiatives and late-stage acceleration programs. Grapheal and RheaVita have already made investments in the enabling technologies they are developing. Novalis will continue to use its strong network in the Benelux area and intends to expand its investments throughout Western Europe and the United States.
Novalis invests early and focuses on capital-light ideas where modest investments can generate substantial value using software, intellectual property, tools, and other enabling technologies that can transform healthcare. Novalis has a strong track record of turning ideas into profitable businesses by using extensive networks.
Novalis Fund 1 was established in September 2018 with a total capitalization of €4 million, which was invested in eight companies, the majority of which were located in the Benelux region. BioLizard, Cergentis, Enzyre, Epify, Fertiga, myNEO, and OHMX.bio are among them. A first exit occurred when doc.ai, a US portfolio company, was acquired by Sharecare as part of an IPO.
About Novalis Biotech Acceleration
Novalis Biotech is an early-stage venture capital investor in healthcare-revolutionizing technologies. The company's main competence is digitalization in the life sciences, focusing on capital-light "enabling technologies" such as bioinformatics, artificial intelligence, genomics, personalized medicine, research or manufacturing tools, and diagnostics.
Read More
MEDICAL
AvantGen | January 12, 2021
AvantGen, Inc., a San Diego-based biotechnology organization with a variety of innovation stages for neutralizer revelation and enhancement, and novel NK and T cell engager age, today reported permitting of a board of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.
Utilizing its novel yeast show framework and huge different human antibody response libraries, AvantGen has distinguished a board of high partiality human monoclonal antibody clones that quandary to two unmistakable epitopes on the receptor restricting space of the SARS-CoV-2 spike protein. After official, the antibodies block the spike protein from cooperating with ACE2 and subsequently forestall infection prompted cell-slaughtering, otherwise called cytopathic impact. Furthermore, one gathering of immune response clones can likewise obstruct ACE2's cooperation with SARS-CoV-1, showing that the epitope perceived by this gathering of clones is rationed between SARS-CoV-1 and - 2, conceivably presenting more extensive killing action against this family of coronaviruses.
In a recognized animal model of SARS-CoV-2 contamination, AvantGen's lead applicant antibody has been appeared to fundamentally diminish viral load in, and macrophage infiltration of, the lungs, as well as reduce disease severity.
Read More